Evidence map›Paper›PMID 40088279›Full record

Trial reportUrolithiasis2025

A double-blind, randomized, placebo-controlled study to evaluate the efficacy of Oxybutynin Chloride Extended-Release tablets on the double-J stent related symptoms following uncomplicated ureteroscopic lithotripsy.

Kuo-How Huang, Tsung-Yi Hsieh, Po-Ming Chow, Yuan-Ju Lee, Hsu-Che Huang, I-Ni Chiang, Teng-Kai Yang

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Urolithiasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kuo-How Huang *Department of Urology, National Taiwan, National Taiwan University Hospital, University College of Medicine, Taipei, Taiwan.
Tsung-Yi HsiehDepartment of Urology, National Taiwan, National Taiwan University Hospital, University College of Medicine, Taipei, Taiwan.
Po-Ming ChowDepartment of Urology, National Taiwan, National Taiwan University Hospital, University College of Medicine, Taipei, Taiwan.
Yuan-Ju Lee *Department of Urology, National Taiwan, National Taiwan University Hospital, University College of Medicine, Taipei, Taiwan.
Hsu-Che HuangDivision of Urology, Department of Surgery, Yonghe Cardinal Tien Hospital, New Taipei City, Taiwan.
I-Ni ChiangDepartment of Urology, National Taiwan, National Taiwan University Hospital, University College of Medicine, Taipei, Taiwan.
Teng-Kai YangDivision of Urology, Department of Surgery, Yonghe Cardinal Tien Hospital, New Taipei City, Taiwan. circulas1@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To evaluate the effects of Oxybutynin Chloride Extended-Release Tablets (Oxbu) on double-J stent-related symptoms following uncomplicated ureterosocpic lithotripsy (URSL). This is a double-blind, randomized, placebo-controlled study with a total of 120 subjects with ureteral calculi receiving double-J stent insertion following URSL. Subjects who meet the inclusion and exclusion criteria will be randomly assigned to Oxbu or placebo group. All patients completed a structured questionnaire assessing the stent-related symptoms one week after operation. The clinical data and stent characteristics were recorded as well. The severity of stent-related symptoms was compared between two groups. The mean age were 58.2 years both in Oxbu group and control group, and the demographic data were all comparable between the two groups. Oxbu group had significant improvement for stent related pain score (-0.47 points, P < 0.01) and quality of life score (-0.17 points, P < 0.01) compared to the control group. The male subgroup showed that Oxbu had less urgency item score (-0.59 points, P < 0.05). The subgroup analysis for female showed that Oxbu had more decrease in the intermittency item score (-0.89 points, P = 0.043) and aged < 50 showed Oxbu had more decrease in Overactive Bladder Symptoms Score total score and urgency item score (-0.8 and - 0.6 points, all P < 0.05). This study showed that Oxbu decreases the severity of double-J stent related pain and the quality of life score for patients received URSL. In the IPSS and OABSS item, the intermittency and urgency are improved in the Oxbu group. In conclusion, Oxbu treatment had beneficial effects to improve the severity of stent related symptoms.

Indexed as

LithotripsyMandelic AcidsMuscarinic AntagonistsPostoperative PainStentsUreteral CalculiUreteroscopyAdultAgedDelayed-Action PreparationsDouble-Blind MethodFemaleHumansMaleMiddle AgedQuality of LifeDelayed-Action PreparationsMandelic AcidsMuscarinic AntagonistsoxybutyninTabletsLower urinary tract symptomsOxybutynin chlorideUreteral stent

Identifiers

PMID40088279

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.